Literature DB >> 33328254

Modeled Reductions in Late-stage Cancer with a Multi-Cancer Early Detection Test.

Earl Hubbell1, Christina A Clarke2, Alexander M Aravanis2,3, Christine D Berg4.   

Abstract

BACKGROUND: Cancer is the second leading cause of death globally, with many cases detected at a late stage when prognosis is poor. New technologies enabling multi-cancer early detection (MCED) may make "universal cancer screening" possible. We extend single-cancer models to understand the potential public health effects of adding a MCED test to usual care.
METHODS: We obtained data on stage-specific incidence and survival of all invasive cancers diagnosed in persons aged 50-79 between 2006 and 2015 from the US Surveillance, Epidemiology, and End Results (SEER) program, and combined this with published performance of a MCED test in a state transition model (interception model) to predict diagnostic yield, stage shift, and potential mortality reductions. We model long-term (incident) performance, accou.

Entities:  

Mesh:

Year:  2020        PMID: 33328254     DOI: 10.1158/1055-9965.EPI-20-1134

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  11 in total

1.  Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access.

Authors:  Patricia A Deverka; Michael P Douglas; Kathryn A Phillips
Journal:  Health Aff (Millwood)       Date:  2022-03       Impact factor: 6.301

2.  The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11, 2171.

Authors:  Eric A Klein; Tomasz M Beer; Michael Seiden
Journal:  Diagnostics (Basel)       Date:  2022-05-17

3.  Clinical validation of a next-generation sequencing-based multi-cancer early detection "liquid biopsy" blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study.

Authors:  Andi Flory; Kristina M Kruglyak; John A Tynan; Lisa M McLennan; Jill M Rafalko; Patrick Christian Fiaux; Gilberto E Hernandez; Francesco Marass; Prachi Nakashe; Carlos A Ruiz-Perez; Donna M Fath; Thuy Jennings; Rita Motalli-Pepio; Kate Wotrang; Angela L McCleary-Wheeler; Susan Lana; Brenda Phillips; Brian K Flesner; Nicole F Leibman; Tracy LaDue; Chelsea D Tripp; Brenda L Coomber; J Paul Woods; Mairin Miller; Sean W Aiken; Amber Wolf-Ringwall; Antonella Borgatti; Kathleen Kraska; Christopher B Thomson; Alane Kosanovich Cahalane; Rebecca L Murray; William C Kisseberth; Maria A Camps-Palau; Franck Floch; Claire Beaudu-Lange; Aurélia Klajer-Peres; Olivier Keravel; Luc-André Fribourg-Blanc; Pascale Chicha Mazetier; Angelo Marco; Molly B McLeod; Erin Portillo; Terry S Clark; Scott Judd; C Kirk Feinberg; Marie Benitez; Candace Runyan; Lindsey Hackett; Scott Lafey; Danielle Richardson; Sarah Vineyard; Mary Tefend Campbell; Nilesh Dharajiya; Taylor J Jensen; Dirk van den Boom; Luis A Diaz; Daniel S Grosu; Arthur Polk; Kalle Marsal; Susan Cho Hicks; Katherine M Lytle; Lauren Holtvoigt; Jason Chibuk; Ilya Chorny; Dana W Y Tsui
Journal:  PLoS One       Date:  2022-04-26       Impact factor: 3.752

4.  Circulating Cancer Biomarkers.

Authors:  Anna Lokshin; Robert C Bast; Karin Rodland
Journal:  Cancers (Basel)       Date:  2021-02-15       Impact factor: 6.639

Review 5.  Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs.

Authors:  Jason Chibuk; Andi Flory; Kristina M Kruglyak; Nicole Leibman; Alexis Nahama; Nilesh Dharajiya; Dirk van den Boom; Taylor J Jensen; Jeffrey S Friedman; M Richard Shen; Francisco Clemente-Vicario; Ilya Chorny; John A Tynan; Katherine M Lytle; Lauren E Holtvoigt; Muhammed Murtaza; Luis A Diaz; Dana W Y Tsui; Daniel S Grosu
Journal:  Front Vet Sci       Date:  2021-03-23

6.  Clinical correlates of circulating cell-free DNA tumor fraction.

Authors:  Joerg Bredno; Jafi Lipson; Oliver Venn; Alexander M Aravanis; Arash Jamshidi
Journal:  PLoS One       Date:  2021-08-25       Impact factor: 3.240

Review 7.  Opportunities for Early Cancer Detection: The Rise of ctDNA Methylation-Based Pan-Cancer Screening Technologies.

Authors:  Nicolas Constantin; Abu Ali Ibn Sina; Darren Korbie; Matt Trau
Journal:  Epigenomes       Date:  2022-02-04

8.  The Early Detection of Breast Cancer Using Liquid Biopsies: Model Estimates of the Benefits, Harms, and Costs.

Authors:  Esmée K J van der Poort; Nicolien T van Ravesteyn; Jeroen J van den Broek; Harry J de Koning
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

9.  Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial.

Authors:  Richard D Neal; Peter Johnson; Christina A Clarke; Stephanie A Hamilton; Nan Zhang; Harpal Kumar; Charles Swanton; Peter Sasieni
Journal:  Cancers (Basel)       Date:  2022-10-01       Impact factor: 6.575

10.  Blood-Based Liquid Biopsy for Comprehensive Cancer Genomic Profiling Using Next-Generation Sequencing: An Emerging Paradigm for Non-invasive Cancer Detection and Management in Dogs.

Authors:  Kristina M Kruglyak; Jason Chibuk; Lisa McLennan; Prachi Nakashe; Gilberto E Hernandez; Rita Motalli-Pepio; Donna M Fath; John A Tynan; Lauren E Holtvoigt; Ilya Chorny; Daniel S Grosu; Dana W Y Tsui; Andi Flory
Journal:  Front Vet Sci       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.